Connect Sign In
The Fall 2022 edition of Magnify: The Art and Science of Diagnostic Medicine, shares how ARUP has applied what it learned from COVID-19 to improve operations, services, and, ultimately, patient care.
Based on data from 21,916 participants in 33 studies, the Association for the Advancement of Blood and Biotherapies (AABB) has issued guidelines for use of convalescent plasma in COVID-19 treatment.
The National Institute of Allergy and Infectious Diseases has awarded Medical Director Allison Carey, MD, PhD, $1.5 million over five years to fund her groundbreaking research.
A new study for which ARUP provided COVID-19 testing and expertise found that emergency department workers early in the pandemic faced the highest risk of infection from community spread.
The Summer 2022 edition of Magnify, now online, features a look at the challenges of autoimmune neurologic testing, our experts in this area, and recent awards, and catches up with a former fellow.
ARUP medical directors and scientists will share their research and expertise in areas like lab stewardship, biochemical genetics, and neonatal drug testing at AACC’s 2022 annual meeting in Chicago.
Scientist Michael T. Pyne shares ARUP’s challenges and process of developing a next generation sequencing (NGS) test for HIV-1 antiretroviral drug resistance.
ARUP experts say that the VALID Act, which would require FDA approval of all lab-developed tests, would add administrative and financial burdens to an already safe and effective validation process.
ARUP experts are to give six talks and poster presentations at the flagship annual meeting of the American Society for Microbiology (ASM) in Washington, D.C.
Two members of the ARUP Healthcare Advisory Services team have built the basis for an open access database that could change the way researchers perform meta-analyses.
Society's growing and changing understanding of how race, ethnicity, or ancestry (REA) is experienced and interpreted is prompting many clinical labs to reexamine practices related to REA data.
ARUP was among a few blood centers that contributed COVID-19 convalescent plasma (CCP) to a national clinical trial that found a >50% reduction in risk of hospitalization with early CCP treatment.
